GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death

Antivir Ther. 2012;17(7):1271-9. doi: 10.3851/IMP2309. Epub 2012 Sep 5.

Abstract

Background: GB virus C (GBV-C) coinfection is associated with reduced immune activation and a block in CD4(+) T-cell proliferation following interleukin-2 (IL-2) therapy in HIV-infected individuals. We examined peripheral blood mononuclear cells (PBMCs) from HIV-infected subjects with and without GBV-C viraemia to determine if GBV-C correlated with reactivation of latent HIV, T-cell proliferation or T-cell survival following in vitro activation with phytohaemagglutinin A and IL-2 (PHA/IL-2).

Methods: HIV-infected subjects whose HIV viral load was suppressed on combination antiretroviral therapy (cART) for >6 months were studied. PBMCs were cultured with and without PHA/IL-2 and monitored for HIV reactivation, proliferation and survival. GBV-C viraemia and in vitro replication were detected by real-time RT-PCR. HIV reactivation was determined by measuring HIV p24 antigen in culture supernatants. Proliferation was measured by counting viable cells and survival measured by flow cytometry.

Results: Of 49 HIV-infected individuals, 26 had GBV-C viraemia. Significantly less HIV reactivation and PBMC proliferation following in vitro activation with PHA/IL-2 was observed in samples from GBV-C viraemic subjects compared with non-viraemic controls. Following 5 weeks in culture, GBV-C replication was associated with preservation of CD4(+) and CD8(+) T-cells compared with non-viraemic controls.

Conclusions: GBV-C appears to inhibit immune activation and IL-2 signalling pathways, which might contribute to a reduction in reactivation of latent HIV from cellular reservoirs. In addition, GBV-C viraemia was associated with a reduction in activation-induced T-cell death. GBV-C-associated T-cell effects could contribute to the observed protective effect of GBV-C coinfection in HIV-infected individuals.

Publication types

  • Research Support, American Recovery and Reinvestment Act
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / virology
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / virology
  • Case-Control Studies
  • Cell Death
  • Cell Proliferation
  • Cell Survival
  • Cells, Cultured
  • Coinfection / virology
  • Flaviviridae Infections / immunology
  • Flaviviridae Infections / virology
  • Flow Cytometry
  • GB virus C / pathogenicity*
  • GB virus C / physiology
  • HIV Core Protein p24 / analysis
  • HIV Core Protein p24 / immunology
  • HIV Infections / immunology*
  • HIV Infections / virology
  • HIV-1 / pathogenicity
  • Hepatitis, Viral, Human / immunology
  • Hepatitis, Viral, Human / virology
  • Humans
  • Interleukin-2 / immunology
  • Interleukin-2 / pharmacology
  • Lymphocyte Activation*
  • Phytohemagglutinins / immunology
  • Phytohemagglutinins / pharmacology
  • Signal Transduction
  • Viral Load
  • Viremia / virology
  • Virus Activation*
  • Virus Latency*

Substances

  • HIV Core Protein p24
  • Interleukin-2
  • Phytohemagglutinins